The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Yokose N, Ogata K, Tamura H, An E, Nakamura K, Kamikubo K, Kudoh S, Dan K, Nomura T

Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma.

British journal of cancer. 1998;77(12):2286-90

Hasegawa Y, Ninomiya H, Kamoshita M, Ohtani K, Kobayashi T, Kojima H, Nagasawa T, Abe T

Interstitial pneumonitis related to granulocyte colony-stimulating factor administration following chemotherapy for elderly patients with non-Hodgkin's lymphoma.

Internal medicine (Tokyo, Japan). 1997;36(5):360-4

Bukowski RM, Murthy S, McLain D, Finke J, Andresen S, Tubbs R, Bauer L, Gibson V, Budd GT, Thomassen MJ

Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer: clinical and immunologic effects.

Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy. 1993;13(4):267-74

Katoh M, Shikoshi K, Takada M, Umeda M, Tsukahara T, Kitagawa S, Shirai T

Development of interstitial pneumonitis during treatment with granulocyte colony-stimulating factor.

Annals of hematology. 1993;67(4):201-2